Biologics is one of Syngene’s core service offerings comprising integrated services across the drug discovery, development and manufacturing continuum. We are committed to incrementally adding new layers of expertise to drive continued innovation. Solving our partners’ complex research and manufacturing problems, has been the hallmark of our success, and sustainable long-term relationships.
In this video, our VP of manufacturing, Alex Del Priore discusses the implications of the rapidly increasing demand for biologics development and production, how the biologics industry is responding to that demand, and the important factors to consider when selecting a CDMO partner for biologics manufacturing.
Our Biologics Discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. Our services cover recombinant DNA engineering, cell line development, hybridoma technology, next-generation sequencing, and protein sciences (purification & crystallography). Additionally, we also support integrated drug discovery for biologics with SynVent – Syngene’s platform for fully integrated therapeutic discovery and development.
We work with diverse biological entities like monoclonal antibodies, bispecifics, antibody fragments, recombinant proteins, glycoproteins, Pegylated proteins, subunit protein vaccines, mRNA, microbial (E. coli and Pichia), microbiome live biotherapeutic product (LBP) and multimeric protein complexes.
We are a fully integrated custom biomanufacturer. Our biologics manufacturing facility caters to multi-product production campaigns simultaneously, based on single-use technology platform.
Syngene reported a 19% growth in revenue from operations for the entire year of FY22. Watch this video as our CEO and MD, Jonathan Hunt, speaks about Syngene’s performance, the outlook for FY 23, Syngene’s contribution in the fight against the pandemic, focus areas for the coming year, and more.